A single dose of Zostavax is recommended for adults aged ≥60 years who have not previously received Zostavax. A dose is particularly recommended for adults who are 70–79 years of age.

In people aged 60–69 years, the incidence of both herpes zoster and post-herpetic neuralgia is high, and Zostavax is efficacious.1 However, the exact duration of vaccine efficacy is not known. Protection after a single vaccine dose wanes over time.2,3 The need for revaccination is not yet determined.

People aged 70–79 years are expected to benefit the most from routine vaccination with Zostavax. Although Zostavax efficacy against herpes zoster is lower in this age group than in people aged 50–69 years, people ≥70 years of age have a higher risk of both herpes zoster and post-herpetic neuralgia.1,4,5

In people aged ≥80 years, Zostavax is less efficacious. People of this age may still receive some clinical benefit from being vaccinated.6

Please refer to the ATAGI clinical statement on the clinical use of Zoster vaccine in Australia.

See Vaccine information and Epidemiology.

Page history

Last updated: 
4 May 2022
Last reviewed: 
4 May 2022